GSCG Announces Upcoming Stem Cell Training Course in Dubai
The Global Stem Cells Group, a multi-disciplinary community of scientists and physicians that are collaborating to treat diseases and lessen human suffering through the advancement of the field of regenerative medicine has announced plans for a training in Dubai, UAE on November 11th-12th.
This training will be one of the second one of 2022, reaffirming the Global Stem Cells Group’s presence in Europe as a key player in the field of regenerative medicine. Members from both Global Stem Cells Group & the International Society for Stem Cell Application’s Dubai Chapter will be there to assist in expanding research for and the practice of regenerative medicine across Europe.
“We hope that more and more physicians and clinics will take up the benefits of regenerative medicine.As we continue to train patients with the GCell Machine, ” Says Benito Novas, founder and CEO of the Global Stem Cells Group
This training is intended to teach physicians the value and process behind incorporating regenerative medicine into their own clinical practice. This includes a theoretical portion that goes over basic regenerative medicine biology and its application, but also includes a Hands-On portion in which doctors, in a controlled environment and guided by a team of medical professionals, will have the opportunity to see procedures be performed just a few feet away, and then get the opportunity to try it for themselves.
This training will also teach physicians how to utilize the GCell Machine to perform regenerative medicine therapies. GCell is a tissue homogenization device that is revolutionizing the future of regenerative medicine. It is an extremely compact, all-in-one unit that can homogenize and isolate the stem cells from an adipose sample. GCell’s process of homogenizing with a system of precise blades and filtering ensures that the sample can be processed within an hour, with little input from the physician when the machine begins to do its work.
Once the process is over, the end result is a final product that can be administered to patients within an hour after the initial tissue extraction. This is a far cry from the previous, muti-hour long treatments that physicians have grown accustomed to, and the shortened timespan and simplicity of the procedure is something that both doctors and their patients will greatly appreciate.
If you are interested in enrolling in this upcoming event, or to learn more about the different training opportunities available, you can visit us at our training website.
About Global Stem Cells Group
Global Stem Cells Group (GSCG) is a worldwide network that combines seven major medical corporations, each focused on furthering scientific and technological advancements to lead cutting-edge stem cell development, treatments, and training. The united efforts of GSCG’s affiliate companies provide medical practitioners with a one-stop hub for stem cell solutions that adhere to the highest medical standards.
Global Stem Cells Group is a publicly traded company operating under the symbol MSSV. https://finance.yahoo.com/quote/mssv/
- Published in Press Release
How Exosome Therapy Differ from Stem Cell Therapy
Exosomes are potent microvesicles released by adult mesenchymal stem cells. They have the ability to help restore cells in the body by improving cell to cell communication.
Exosomes are not cells, and they are smaller than cells. When compared to adult stem cells, exosomes have much more growth factors which give them a better clinical and aesthetic potential than stem cells.
It’s a cell-free cell therapy, this makes it safer compared to other cellular therapy, because there’s no risk of rejection in graft Vs host.
Unlike some other cellular therapies, exosomes do not produce host graft reactions, because they do not carry HLA genetic information and are not cells but extracts of the cells (released by cells).
Exosomes have a superior regenerative capacity, because they are obtained from newborn umbilical cord tissue mesenchymal cells, which means they have not been exposed to any contaminating or toxic agent because our cells are as healthy as our body.
Exosomes improve the signaling between cells, thereby making them useful to revitalize, rejuvenate, restore, and cause anti-inflammatory effects in the body.
When compared to autologous adult stem cells, exosomes have much more healthy growth factors which gives them a better clinical and aesthetic potential than stem cells.
Exosomes are less complicated products to transport because the cells used in cellular therapy must be applied to the patient very quickly because they are live cells. In the laboratory, once they are thawed the doctors have limited time to apply them. However, with exosomes, they last longer, because as they are proteins they do not denature and can last for longer periods.
Exosomes is a superior product to autologous treatments because they do not require a surgical procedure, they come in a vial that can be injected directly, significantly reducing the risk and complications of a surgical procedure.
It is a superior product to autologous stem cell therapy because the patient’s cells have the same age and the same quality. For example, if a patient is a smoker and intoxicated, obviously the health of his cells is not the best. That is why the most indicated product is a donor product that is pure and free of toxins.
Mesenchymal cell-derived exosomes are preferably used in regenerative medicine. These cells are excellent regenerative cells due to their multipotent nature, therefore MSCs derived exosomes are superior to other exosomes products.
The Cellgenic lyophilized exosomes are derived from mesenchymal cells, which makes it superior to other exosome products, because mesenchymal cells have superior and excellent regenerative capacity.
This is why exosome therapy, especially Cellgenic lyophilized exosomes should be a doctor’s first choice.
- Published in Blog
Applications of Exosomes in Regenerative Medicine
In recent years, the application of exosomes in regenerative medicine has been growing. Also, many more potential applications of exosomes in regenerative medicine are still being studied.
In this article, you’ll learn the functions of exosomes and up-to-date applications of exosomes in regenerative medicine.
What are exosomes?
Exosomes are tiny vesicles that play a crucial role in cell to cell communication. Every cell in our body produces exosomes, to give information to the neighboring cells or long-distance cells, to change their behavior or to simply share information.
They transfer genetic information, proteins, and receptors, and they are capable of changing the behavior of one cell to the other. They have the ability to increase cell replication and other substances crucial for tissue regeneration.
Functions of exosomes
The major function of exosomes is to improve intercellular communication by releasing effectors and signaling molecules between cells.
Every cell in our body produces exosomes, to give information to the neighboring cells, or long distance cells, to change their behavior or to simply share information.
They transfer genetic information, proteins, and receptors, and are capable of changing the behavior of one cell to the other. They can increase cell replication and other substances crucial for tissue regeneration.
Exosomes affect all aspects of cell biology and are useful for improving intercellular communication.
Various applications of exosomes in regenerative medicine.
Exosomes have various clinical applications due to their high potency, reduced immunogenicity, and ability to cross physiological barriers such as the blood-brain barrier.
In regenerative medicine, exosomes can be used in a point of care environment for a lot of aesthetic and therapeutic purposes.
The Use of Exosomes in Hair therapy
Exosomes can be used in the early stages of hair loss to re-grow and regenerate hair.
The good thing about using exosomes for hair loss is that they can be used in both men and women.
Exosomes can help stimulate hair growth and prevent hair loss. Clinical results have also shown the efficacy of exosomes in alopecia areata.
Exosomes from follicular stem cells are said to inhibit hair loss and promote hair growth.
In the earlier stages of hair loss, hair can be regrown and regenerated in men and women by administering exosomes and growth factors.
After the first round of exosome therapy, noticeable change can be seen in 2 or 3 months but the most significant changes start from 6 to 12 months.
The Use of Exosomes in Skin-Regeneration
There are so many research and clinical trials surrounding the application of exosomes in skin treatment.
The benefits of exosome therapy in skin regeneration because of their ability to directly stimulate target cells, non-immune rejection and high stability.
These are some of the abilities of exosomes in skin regeneration:
- Regulation of inflammation
- Synthesis of collagen
- Angiogenic effect
The Anti-aging effect of exosomes
Exosomes can be used to restore aging tissues of the body due to their outstanding regenerative ability.
Signs of aging manifest due to the skin’s inability to regenerate itself, exosomes can help to maintain the skin’s elasticity and strength.
Exosome therapy is changing the approach to anti-aging treatment. The rejuvenation capability of exosomes is a great way to make your patients feel young again.
It revitalizes senescent cells by repairing damage due to aging.
With exosomes, you are improving longevity by reversing the cells that are dying due to aging.
Exosomes in Pain management
Exosome therapy can be used to relieve pain by subduing pain signals, reducing inflammation and repairing damaged tissues.
The application of Exosome in inflammatory conditions.
Exosomes can decrease inflammation, regenerate cells and modulate the immune system.
Osteoarthritis: MSC-derived exosomes can reduce the joint inflammation in osteoarthritis and also stimulates cartilage regeneration and the repair of damaged tissues.
Tendinitis: Tendinitis is the inflammation of tendons. Exosomes can reduce the inflammation associated with tendinitis and repair torn tendons and muscles.
Due to the potency of exosomes and its paracrine effect, the potential capabilities of exosomes are still being discovered and studied.
At Cellgenic, we prepare easy to transport and administer Lyophilized exosomes, suitable for use in regenerative medicine.
- Published in Blog
ISSCA Members to Present in the XXV Congreso Internacional de Medicina, Cirugia Estética y Obesidad
The XXV Congreso Internacional de Medicina, Cirugia Estética y Obesidad will take place in CDMX, México on July 13,14 and 15, 2022. The International Society for Stem Cell Application (ISSCA) will be actively taking part in the congress. The ISSCA is a multidisciplinary community of physicians and scientists with a mission to advance the science, technology, and practice of regenerative medicine to treat diseases and lessen human suffering through science, technology, and regenerative medicine. Several ISSCA members will be presenting or giving demonstrations on the latest protocols and technologies in regenerative medicine.
- Benito Novas, the managing director of the ISSCA from the USA, will give a talk about Digital Marketing in Cash-Based Practices. Benito Novas is a global entrepreneur, manager, and keynote speaker, who specializes in marketing focused on biotechnology, life sciences, and healthcare development. He has served as the director of the ISSCA since 2016. His published books in Aesthetic Practice and Digital Marketing can be found here. In his presentation this July, he will share his visionary approach to healthcare management and regenerative medicine. Congress attendees will have the opportunity to learn why doctors must use digital marketing strategies to grow a successful practice. Benito Novas will provide tips to attendees on how to capitalize on social media trends to grow practice influence.
- Dr. Maritza Novas, the ISSCA director of education from the USA, will talk about Allogeneic Therapies and Stromal Cell Exosomes. The use of allogeneic therapy is one of the most attractive alternatives to autologous products and is of utmost interest to researchers in recent years. Exosomes serve as mediators for cell-to-cell communication and can be used as cell-free therapeutics for their special characteristics. Dr. Maritza Novas has been in aesthetic and anti-aging medicine since 2001. She is globally recognized for her work in regenerative medicine and dedicated service in education.
- Dr. Silvina Pastrana, the Argentina chapter director of the ISSCA from Argentina, will present on Fundamentals of Cellular Therapies and Mesenchymal Stem Cells (MSC). Dr. Pastrana heads a staff of medical specialists in orthopedics, rheumatology, medical clinic, and cosmetic surgery, performing procedures that incorporate stem cell therapies. She has been serving as a staff surgeon for the Hospital Dr. Prof. Luis Güemes for 21 years.
Besides the above presentations, look forward to sessions in the practical portion of the congress, where the following ISSCA members will show the latest protocols and technologies in regenerative medicine:
- Dr. Julio Ferreira (Argentina), Cosmetic Surgery / Aesthetic Medicine
- Dr. Andrea Lapeire (Argentina), Aesthetic Medicine
- Dr. Maritza Novas (USA), ISSCA Director of Education in the USA
- Dr. Silvina Pastrana (Argentina), Chapter Director of ISSCA in Argentina
The ISSCA members are the leaders in setting standards and promoting excellence in the field of regenerative medicine, related education, certification, research, and publications. The Global Stem Cells Groups (GSCG) is a group of companies, including the ISSCA and other members, dedicated to facilitating stem cell research and medicine. Making the benefits of stem cell medicine a reality for both doctors and patients worldwide is the goal of the GSCG. To learn more, visit our sites at the ISSCA and the GSCG.
- Published in Press Release
How much does exosome therapy cost?
Exosome therapy is the new buzz in the regenerative medicine industry because of how it can repair and regenerate your cells and tissues.
Exosome therapy is safer compared to other cellular therapy because it’s a cell-free therapy with no risk of rejection.
Exosome therapy will be beneficial to you if you’re dealing with conditions such as sport injuries, tissue regeneration, hair loss, erectile dysfunction, chronic pain and so many other applications .
In this article, you’ll be learning the cost of exosome therapy and how you can benefit from exosome therapy.
How the cost of exosome therapy is determined
All cells produce exosomes, which are microvesicles that contain biochemical and genetic information.
Hence, the cost of an exosome product (used in exosome therapy) will depend on what type of cell line (raw tissue source) used to extract the exosomes.
The first factor to determine the cost of an exosome product depends on the quality of the tissue source.
The most commonly used tissue types are cord blood, amniotic fluid and mesenchymal cell cultures.
Exosomes derived from mesenchymal cell cultures are the most difficult to obtain but offer the greatest therapeutic potential.
How much does exosome therapy cost?
The average cost of exosome therapy is $4,900, but the price can be anything from $3,500 – $6,500.
It’s also important to note that the price depends on your specific needs and your treatment plan, as decided by the doctor.
The doctor will schedule a consultation with you to determine your personalized treatment plan.
The exosome therapy can either be given as an IV infusion or as localized injections, depending on the purpose of the therapy.
Exosomes are very useful to revitalize, rejuvenate, restore, and reduce inflammations in the body.
Here are some ways you can benefit from exosome therapy
Hair loss therapy: If you’re in the early stages of hair loss, with exosome therapy you can regenerate your hair whether you’re a man or woman. After exosome therapy, you’ll start seeing new hair growth in as little as two to three months with very significant results showing 6 months or 1 year later.
Chronic pain: In case you’re experiencing chronic pain due to degenerative conditions such as arthritis, exosomes can help to subdue the pain by regenerating the cells and helping the body work better.
Degenerative conditions: If you’re struggling with degenerative medical conditions such as osteoarthritis and musculoskeletal injuries, exosome therapy can help your body repair the damage done to your cells by these conditions, prevent them from getting better, and help you to feel better.
Skin therapy: exosome therapy can reduce inflammation in the skin by improving the strength and elasticity of the skin.
Anti-aging: if you would like to retain your youthful glow, exosome therapy can make you feel young again by rejuvenating your skin due to its ability to reverse the cells dying due to aging.
Where can you get exosome therapy?
Cellular hope institutes provide exosome therapy for patients looking for better outcomes for various conditions.
The exosomes used at Cellular Hope Institute are obtained from umbilical cord tissue that is discarded after a new birth , which means these Exosomes have not been exposed to any contaminating or toxic agent because our cells are as healthy as our body. This gives it a higher capacity to regenerate your cells and tissues.
- Published in Blog
Culture Expanded MSCs
Mesenchymal Stem Cells (MSCs) are the most commonly used cells in stem cell therapy and regenerative medicine, due to their high and multi-potency. Mesenchymal Stem Cells (MSCs) can be isolated from different tissues in the body.
In this article, you’ll be learning about culture-expanded MSCs, how MSCs can be expanded, The potency of MSCs and the type of cells they can differentiate into.
What are culture expanded Mesenchymal Stem cells?
Mesenchymal stem cells are high potent cells used for cellular therapy and isolated from different parts of the body. Mesenchymal stem cells can be used to improve the patient outcome in diseases and conditions such as autoimmune diseases, degenerative diseases, nerve damage, diabetes mellitus, bone problems etc.
For every patient, millions of mesenchymal stem cells are needed and the exact amount varies according to disease, route of administration, administration frequency, weight, and age of patient.
Mesenchymal stem cells are expanded in a culture media, on a large scale in order to obtain the required quantity of cells needed for cellular therapy.
Culture expanded MSCs: How does it work?
Expanding Mesenchymal stem cells in a media involves step by step process of isolation and expansion.
Mesenchymal Stem Cells Isolation
Mesenchymal stem cells can be isolated from different tissues in the human body such as adipose tissues, dental pulp, human bone marrow, umbilical cord tissue, umbilical cord blood, peripheral blood and synovium.
Mesenchymal stem cells are expanded in culture to increase their yield and amplify their desired functions and potency.
Although the population of Mesenchymal Stem Cells obtained will vary from donor to donor, here are some steps to follow:
· Acquire fresh tissue extracts in strictly aseptic conditions, to maintain purity.
· To remove any cell clusters, you have to filter the cell suspension with a 70-mm filter mesh
· Use a centrifuge to roll the cells for about 5 minutes at 500g
· Suspend the cells again the cells to measure the cell viability and yield using Trypan blue exclusion
· Use in T75 culture dishes to culture the cells in 10 mL of complete MSC medium at a density of 25 × 106 cells/mL. You can then go on to Incubate the plates at 37 °C with 5% CO2 in a humidified chamber without any interruption.
· When it’s past 3 h, remove the non-adherent cells that accumulate on the surface of the dish by changing the medium and replacing it with 10 mL fresh complete medium.
· After an additional 8 h of culture, add 10ml fresh complete medium as a replacement for the existing medium. You’ll have to repeat this step every 8 h for up to 72 h of initial culture.
· Cells can be frozen in MSC growth media plus 10% DMSO (D2650) at a density of 2X106 cells/vial.
Expansion of Mesenchymal Stem Cells in a culture media
Culture expanded mesenchymal cells undergo various stages from the preparation of the culture plate, thawing of Mesenchymal stem cells, and the actual expansion of Mesenchymal stem cells.
The reason behind the cultural expansion of Mesenchymal stem cells is to get them to differentiate into other cell types such as osteoblast, adipocyte, and mesenchymal stromal cells.
In preparation, to expand MSCs in a culture media, you need a culture ware. You can get one plastic or glassware plate and coat it with a sufficient amount of 0.1% gelatin. Don’t forget to aspirate the gelatin solution from the coated plate or flask before you use it.
The next step involves the thawing of the Mesenchymal stem cells, and here are a few steps for you to follow:
After the recommended culture medium and coated culture ware is ready and on standby, remove the vial of Mesenchymal Stem Cells from liquid nitrogen and incubate in a 37C water bath and pay close attention to it, until all the cells are completely thawed. The extent of completely thawed frozen cells and how fast, are what determines the cell viability.
Once the cells have thawed completely, take steps to avoid contamination by disinfecting the walls with 70% ethanol, before you proceed to the next step.
Place the cells in a hood, and carefully transfer the cells to a sterile tube with a pipette (1 or 2ml pipette), Do this in such a way to prevent bubbles.
Then, add drops of Mesenchymal Stem cell expansion medium that have been pre-warmed to 37C to the tube containing the Mesenchymal stem cells.
Be careful to take your time when adding the medium to avoid osmotic shock which could lead to decreased viability.
Proceed to mix the suspension slowly by pipetting up and down two times while avoiding any bubbles.
Place the tube in a centrifuge and centrifuge the tube at 300 x g for 2-3 minutes to roll the cells, and you should not vortex the cells.
After this, then decant as much of the supernatant as possible. These steps are necessary to remove residual cryopreservative (DMSO).
Suspend the cells in a total volume of 10 mL of Mesenchymal Stem Cell Expansion Medium again or any alternative of choice, pre-warmed to 37 °C, containing freshly added 8 ng/mL FGF-2 (F0291).
The next step involves placing the cell suspension onto a 10-cm tissue culture plate or a T75 tissue culture flask.
Maintain the cells in a humidified incubator at 37 °C with 5% CO2.
The next day, exchange the medium with fresh Mesenchymal Stem Cell Expansion Medium (pre-warmed to 37 °C) containing 8 ng/mL FGF-2*. Replace with fresh medium containing FGF-2 every two to three days thereafter.
Isolate the cells when they are approximately 80% confluent, using Trypsin-EDTA and passaged further or frozen for later use.
Expansion of Mesenchymal Stem Cells
Once the cells are actively proliferating and have reached a confluence of approximately 80% (before 100%), you should subculture the cells.
Then remove the medium from the 10-cm tissue culture plate containing the confluent layer of human mesenchymal stem cells, carefully and apply 3-5 mL of Trypsin-EDTA Solution, before proceeding to incubate in a 37 °C incubator for 3-5 minutes.
Crosscheck the culture to see if all the cells are completely detached. Then, add 5 mL Mesenchymal Stem Cell Expansion Medium to the plate.
Swirl the plate mildly to mix the cell suspension. Transfer the separated/isolated cells to a 15 mL conical tube.
Centrifuge the tube at 300 x g for 3-5 minutes to pellet the cells.
Throw the supernatant away and apply 2 mL Mesenchymal Stem Cell Expansion Medium (pre-warmed to 37 °C) containing 8 ng/mL FGF-2 to the conical tube and completely suspend the cells again. Remember not to vortex the cells.
Then, use a hemocytometer to count the number of cells.
Plate the cells at a density of 5,000-6,000 cells per cm2 into the appropriate flasks, plates, or wells in a Mesenchymal Stem Cell Expansion Medium containing 8 ng/mL FGF-2.
Cells can be frozen in MSC growth media plus 10% DMSO (D2650) at a density of 2X106 cells/vial.
Functions of Culture Expanded MSCs
Mesenchymal stem cells are required to be expanded in order for them to be used clinically for therapeutic purposes.
The culture expanded MSCs can be induced to differentiate into adipocytes, osteocytes, hepatocytes, chondrocytes, tenocytes and cardiomyocytes.
Because of its potential to differentiate into different kinds of cells in the body, it can be used to manage liver problems, heart problems, joint and bone problems etc.
Mesenchymal stem cells are also used in tissue regeneration and modulation of the immune system. They possess anti apoptotic, angiogenic, anti fibrotic, and anti-oxidative properties.
However, the quantity of MSCs isolated from body tissues is not enough for clinical and therapeutic applications.
This is why MSCs are expanded in culture to increase their yield for desired therapeutic effect.
- Published in Blog
Why cellular therapies have become a standard in clinics that are betting on biological medicine
Cellular therapy is fast becoming a standard therapy in many regenerative clinics today. Many doctors are no longer questioning the safety and effectiveness of stem cell therapy. This is because various stem cell studies are already describing the benefits of stem cells for patients who are living with chronic and autoimmune health conditions.
This article will be talking about why stem cell therapy have become a standard therapy in clinics, the paracrine effect of stem cells, and other reasons why doctors are adopting stem cells in their clinics.
Benefits of stem cell therapy
Stem cell therapy is an important innovation in medicine because of its regenerative power in the human body. Most disease states are characterized by damaged cells, tissues and organs, which is where stem cell therapy comes in. In stem cell therapy, stem cells are administered into the human body and it replaces the cells damaged by disease or health disorders.
Stem cell research has revealed two major ways of using stem cells to rebuild defective and damaged cells. One of these ways can be seen in procedures like bone marrow transplant, where stem cells are used to replace the damaged cells by engraving, and they then differentiate into the proper cell type. Another mechanism relies on the paracrine effect of stem cells. This procedure of stem cell therapy involves using stem cells isolated from a donor to stimulate the patient’s cells to repair damaged tissues.
Additionally, unlike traditional therapy, stem cells have a wide application. Stem cell therapy is used to manage various degenerative diseases, autoimmune disorders, birth defects, and the research is still ongoing for so many other health conditions where stem cells have shown potential.
Also, there is currently a high demand for aesthetic medicine. Stem cell therapy is a proven alternative to other forms of cosmetology such as plastic surgery. Hence, dermatologists are turning to stem cell therapy to administer anti-aging procedures, skin rejuvenation, hair therapy, micro-needling etc.
The Paracrine effect of stem cells
The paracrine effect of stem cells is one of the most outstanding effects of stem cells. It involves using donor cells to stimulate endogenous repair by harnessing the regenerative power of the human body. It is a mechanism of tissue regeneration that has created new possibilities for managing various conditions using stem cell therapy.
The cells that trigger a paracrine response are; mesenchymal cells, umbilical cord blood, umbilical cord tissue, adipose (fat) tissue and blood cells from a donor’s bone marrow.
The paracrine effect occurs when the donor’s cells send the damaged or defective cells signals to induce self regeneration and repair by secreting some factors and proteins. One of the mechanism by which this paracrine effect is initiated, involves the secretion of cytokines and regulatory proteins by the damaged patient’s cells, these cytokines and proteins act as mediators to stimulate an immune response that attracts the donor cells, this causes the donor cells to release proteins and factors that stimulate the patient’s cells to promote cell proliferation, increase vascularization and blood flow to the areas that needs to heal, while reducing inflammation.
Moreover, research has shown that the paracrine effect of stem cells prevents damaged and diseased cells from dying. They are also therapeutically useful in autoimmune diseases and preventing transplant rejection due to the immune suppression effect they have.
Is stem cell therapy effective?
Doctors are always looking for ways to provide the best possible treatment to their patients, and that is why many clinics are embracing stem cell therapy as a standard, due to its many advantages.
Stem cell therapy is one of the most effective and safest therapy patients can receive, when compared to other existing treatment options. Stem cell therapy is used in promoting patient outcomes in a lot of disease conditions that were previously poorly treated by other alternatives.
Again, as new potentials and ways of applying stem cells are being discovered, doctors are beginning to maximize these benefits in their clinics. Some conditions that are currently treated by stem cells include autoimmune conditions, immunotherapy Car-T cells, chronic obstructive pulmonary disease, neurodegenerative conditions, osteoarthritis, spinal cord injury, aesthetics/anti-aging, sports medicine, autism and multiple sclerosis.
Another reason clinics are adopting stem cell therapy as a standard therapy is because it is easy to administer. A lot of machines such as GCELL {Insert link} which makes the harvesting and processing of stem cells easy and fast, have made the procedures easily adaptable by doctors.
Furthermore, stem cell therapy reduces the treatment and recovery time associated with surgical procedures and other treatment options. This alone is a big factor in why stem cells are becoming a standard therapy in clinics.
Therapeutic uses of stem cells vs traditional medicine
Existing stem cell research has shown how the regenerative effect of stem cells is defining the future of medicine. The major advantage of stem cell therapy over conventional medication-based therapy is its safety. Stem cell therapy is aimed at treating the cause of the disease while traditional medicine targets the symptoms.
Another problem with traditional medical therapy is that it introduces another problem while trying to solve the existing one. As a doctor, you always run the risk of causing harm with each prescription because of various adverse effects that could lead to major organ damage of the kidney, liver etc. On the other hand, patients already know this and they are actively seeking better alternatives, this is why stem cell therapy is fast becoming a standard therapy in clinics.
Moreover, doctors will always be concerned about whether their patients are taking their medications or not. The burden of drug compliance and adherence associated with traditional medical therapy is not always easy to navigate. This is why effective treatment options like stem cell therapy have become a standard therapy in clinics. It only requires the patients having a procedure that repairs and restores damaged cells and tissues in the most natural way.
If you would like to become certified in regenerative medicine using stem cells and other cellular therapy, contact us.
- Published in Blog
ISSCA to Launch Postgraduate Studies Program in Regenerative Medicine
MIAMI, July 20 , 2020— The international Society for Stem Cell Application ISSCA and Medicel Chile have announced plans to launch a post graduate studies program in stem cell therapies and regenerative medicine in 2020.
The program will include Seven days of intensive, interactive training coursework with classroom instruction and laboratory practice through didactic lectures, hands-on practical experience in laboratory protocols and relevant lessons in regulatory practices. Medicel’s Chief Scientific Officer and Other leading Scientists will teach the coursework and perform laboratory instruction, accompanied by a series of guest lecturers from the Global Stem Cells Group faculty of scientists.
Attendees will receive hands-on training in techniques for a variety of laboratory processes, and gain insight into the inner workings of a cGMP laboratory and registered tissue bank. Regenerative medicine experts with more 15 years of experience in the field will train attendees and provide the necessary tools to implement regulatory and clinical guidelines in a cGMP laboratory setting
The graduate course will be scheduled 3 times during 2020 starting February 23rd
“ Our end goal in Launching this Fellowship program is to help physicians that are looking for really advanced and formal training in Cellular Therapies and Regenerative Medicine — We want to provide them the necessary skills and in depth specialization that is lacking in our smaller point of care programs ,” noted Benito Novas ISSCA Public Relations Director
To learn more about the February 2020 certification event in Santiago, or any of the other upcoming certification courses around the world, visit the ISSCA website. www.issca.us
About the International Society for Stem Cells Applications (ISSCA)
The International Society for Stem Cells Applications (ISSCA) is a multidisciplinary
community of scientists and physicians, all of whom aspire to treat diseases and lessen
human suffering through advances in science, technology, and the practice of regenerative
medicine. Incorporated and Trademarked in the United States of America as a non-profit entity, ISSCA is focused on promoting excellence and standards in the field of regenerative medicine.
ISSCA bridges the gaps between scientists and practitioners in Regenerative Medicine.
Their code of ethics emphasizes principles of morals and ethical conducts.
ISSCA’s vision is to take a leadership position in promoting excellence and setting
standards in the regenerative medicine fields of publication, research, education, training,
and certification. ISSCA serves its members through advancements made to the specialty
of regenerative medicine. They aim to encourage more physicians to practice regenerative
medicine and make it available to benefit patients both nationally and globally.
For more information, please visit the ISSCA’s website or send an email to
info@stemcellsgroup.com
About Medicel Chile
Medicel Chile is one of the premiere regenerative medicine treatment centers in the country of Chile, conveniently located in Santiago de Chile, one of the largest metropolitan areas in Latin America. Medicel carries with it a reputation as one of the most scientifically advanced and professional regenerative medicine Laboratories in Chile, and this is in no small part due to its highly-qualified team of scientists and medical professionals and advisers, who research tirelessly to head new breakthroughs in the fields of cellular therapy and cryopreservation, which is the freezing of a stem cell sample to ensure its longevity and freshness, should the patient receiving the service ever wish to use their frozen cells for some future malady.
- Published in News/Events
Conventional and novel stem cell based therapies for androgenic alopecia
Dodanim Talavera-Adame,1 Daniella Newman,2 Nathan Newman1
1American Advanced Medical Corp. (Private Practice), Beverly Hills, CA,
2Western University of Health Sciences, Pomona, CA, USA
Abstract
The prevalence of androgenic alopecia (AGA) increases with age and it affects both men and women. Patients diagnosed with AGA may experience decreased quality of life, depression, and feel self-conscious. There are a variety of therapeutic options ranging from prescription drugs to non-prescription medications. Currently, AGA involves an annual global market revenue of US$4 billion and a growth rate of 1.8%, indicating a growing consumer market. Although natural and synthetic ingredients can promote hair growth and, therefore, be useful to treat AGA, some of them have important adverse effects and unknown mechanisms of action that limit their use and benefits. Biologic factors that include signaling from stem cells, dermal papilla cells, and platelet-rich plasma are some of the current therapeutic agents being studied for hair restoration with milder side effects. However, most of the mechanisms exerted by these factors in hair restoration are still being researched. In this review, we analyze the therapeutic agents that have been used for AGA and emphasize the potential of new therapies based on advances in stem cell technologies and regenerative medicine.
Introduction
The prevalence of androgenic alopecia (AGA) increases with age, and is estimated to affect about 80% of Caucasian men.1 Female AGA, also known as female pattern hair loss, affects 32% of women in the ninth decade of life.2 The consumer market for products that promote hair growth has been increasing dramatically.3 These products promote hair regeneration based on the knowledge about the hair follicle (HF) cycle.4,5 However, in most cases, the mechanisms of action of these products are not well characterized and the results are variable or with undesirable side effects.6 At present, only two treatments for AGA have been approved by the US Food and Drug Administration (FDA): Minoxidil and Finasteride.7–10Although these medications have proved to be effective in some cases, their use is limited by their side effects.11,12 With the emergence of stem cells (SCs), many mechanisms that lead to tissue regeneration have been discovered.13 Hair regeneration has become one of the targets for SC technologies to restore the hair in AGA.14 Several SC factors such as peptides exert essential signals to promote hair regrowth.15,16 Some of these signals stimulate differentiation of SCs to keratinocytes which are important for HF growth.17 Other signals can stimulate dermal papilla cells (DPCs) that promote SC proliferation in the HF.18,19 In this review, we describe HF characteristics and discuss different therapies used currently for AGA and possible novel agents for hair regeneration. These therapies include FDA-approved medications, non-prescription physical or chemical agents, natural ingredients, small molecules, biologic factors, and signals derived from SCs.
HF and SC niche
The HF undergoes biologic changes from an actively growing stage (anagen) to a quiescent stage (telogen) with an intermediate remodeling stage (catagen).4 HFSCs are located in the bulge region of the follicle and they interact with mesenchymal SCs (MSCs) located in the dermal papilla (DP).18 These signal exchanges promote activation of some cellular pathways that are essential for DPC growth, function, and survival, such as the activation of Wnt signaling pathway.19–21 Other signals, such as those from endothelial cells (ECs) located at the DP, are also essential for HF maintenance.22 EC dysfunction that impairs adequate blood supply may limits or inhibits hair growth.22 For instance, Minoxidil, a synthetic agent, is able to promote hair growth by increasing blood flow and the production of prostaglandin E2 (PGE2).7 It has been shown that proteins that belong to the transforming growth factor (TGF) superfamily, such as bone morphogenetic proteins (BMPs), also exert signals to maintain the capacity of DPCs to induce HF growing in vivo and in vitro.23 These BMPs may be released by several cells that compose the follicle, including ECs.24–26 ECs may provide signals for BMP receptor activation in DPCs similar to those signals that promote survival of MSCs in human embryoid bodies composed of multipotent cells.24,25 DPCs have been derived from pluripotent SCs in an attempt to study their potential for hair regeneration in vitro and in vivo.27 Together, dermal blood vessels and DPCs orchestrate a suitable microenvironment for the growth and survival of HFSCs.28,29 Interestingly, the expression of Forkhead box C1 regulates the quiescence of HFSCs located in the bulge region (Figure 1).30 HFSCs are quiescent during mid-anagen and maintain this stage until the next hair cycle.29,30 However, during early anagen stage, these cells undergo a short proliferative phase in which they self-renew and produce new hair.30 Therefore, the bulge region constitutes a SC niche that makes multiple signals toward quiescence or proliferation stages.30–34 It is known that fibroblasts and adipocyte signals are able to inhibit the proliferation of HFSCs.34 Additionally, BMP6 and fibroblast growth factor 18 (FGF18) from bulge cells exert inhibitory effects on HFSC proliferation.34 Dihydrotestosterone (DHT) also inhibits HF growth.35 Agents that reduce DHT, such as Finasteride, promote hair regrowth by inhibiting Type II 5a-reductase.8,14,36 In contrast to these inhibitory effects, DPCs located at the base of the HF provide activation signals (Figure 1).18,34 The crosstalk between DPCs and HFSCs leads to inhibition of inhibitory effects with the resultant cell proliferation toward hair regeneration (anagen).30,31,37 With the self-renewal of HFSCs, the outer root sheath (ORS) forms, and signals from DPCs to the bulge cells diminish in a way that the bulge cells start again with their quiescent stage.4,34As mentioned earlier, Forkhead box C1 transcription factor has an important role in maintaining the threshold for HFSC activation.30 The knockdown of these factors in bulge cells reduces the cells’ threshold for proliferation, and the anagen cycle starts more frequently due to promotion of HFSC proliferation in shorter periods of time.30
Laser therapy
Light amplification by stimulated emission of radiation (LASER) generates electromagnetic radiation which is uniform in polarization, phase, and wavelength.45 Low-level laser therapy (LLLT), also called “cold laser” therapy, since it utilizes lower power densities than those needed to produce heating of tissue. Transdermal LLLT has been used for therapeutic purposes via photobiomodulation.46,47 Several clinical conditions, such as rheumatoid arthritis, mucositis, pain, and other inflammatory diseases, have been treated with these laser devices.48–50 LLLT promotes cell proliferation by stimulating cellular production of adenosine triphosphate and creating a shift in overall cell redox potential toward greater intracellular oxidation.51 The redox state of the cell regulates activation of signaling pathways that ultimately promotes high transcription factor activity and gene expression of factors associated with the cell cycle.52 Physical agents such as lasers have been also used to prevent hair loss in a wavelength range in the red and near infrared (600–1,070 nm).5,47,51,53 Laser therapy emits light that penetrates the scalp and promotes hair growth by increasing the blood flow.54 This increase gives rise to EC proliferation and migration due to upregulation of vascular endothelial growth factor (VEGF) and endothelial nitric oxide synthase.55,56 In addition, the laser energy itself stimulates metabolism in catagen or telogen follicles, resulting in the production of anagen hair.53,54A specific effect of LLLT has been demonstrated to promote proliferation of HFSCs, forcing the hair to start the anagen phase.57
Biologic agents that promote hair growth and their mechanisms of action
SC signaling
Recently, it has been found that SCs release factors that can promote hair growth.16 These factors and their mechanisms of action have been summarized in Table 3. These factors, known as “secretomes”, are able to promote skin regeneration, wound healing, and immunologic modulation, among other effects.58,59 Some of these factors, such as epidermal growth factor (EGF), basic fibroblast growth factor, hepatocyte growth factor (HGF) and HGF activator, VEGF, insulin-like growth factor (IGF), TGF-ß, and platelet-derived growth factor (PDGF), are able to provide signals that promote hair growth.15,60–64 As mentioned before, DPCs provide signals to HFSCs located in the bulge that proliferate and migrate either to the DP or to the epidermis to repopulate the basal layer (Figure 1).32,65 Enhancement in growth factor expression (except for EGF) has been reported when the adipose SCs are cultured in hypoxic conditions.15 Also, SCs increase their self-renewal capacity under these conditions.66–68 Low oxygen concentrations (1%–5%) increase the level of expression of SC factors that include VEGF, basic fibroblast growth factor, IGF binding protein 1 (IGFBP-1), IGF binding protein 2 (IGFBP-2), macrophage colony-stimulating factor (M-CSF), M-CSF receptor (M-CSFR), and PDGF receptor ß (PDGFR-ß).15,69,70 While these groups of factors promote HF growth in intact skin, another group of factors, such as M-CSF, M-CSFR, and interleukin-6, are involved in wound-induced hair neogenesis.71 HGF and HGF activator stimulate DPCs to promote proliferation of epithelial follicular cells.61 Epidermal growth factor promotes cellular migration via the activation of Wnt/ß-catenin signaling.60 VEGF promotes hair growth and increases the follicle size mainly by perifollicular angiogenesis.72 Blocking VEGF activity by neutralizing antibodies reduced the size and growth of the HF.72 PDGF and its receptor (PDGFR-a) are essential for follicular development by promoting upregulation of genes involved in HF differentiation and regulating the anagen phase in HFs.64,73 They are also expressed in neonatal skin cells that surround the HF.73 Monoclonal antibodies to PDGFR-a (APA5) produced failure in hair germ induction, supporting that PDGFR-a and its ligand have an essential role in hair differentiation and development.73 IGF-1 promotes proliferation, survival, and migration of HF cells.69,74 In addition, IGF binding proteins (IGFBPs) also promote hair growth and hair cell survival by regulating IGF-1 effects and its interaction with extracellular matrix proteins in the HF.70 Higher levels of IGF-1 and IGFBPs in beard DPCs suggest that IGF-1 levels are associated with androgens.74 Furthermore, DPCs from non-balding scalps showed significantly higher levels of IGF-1 and IGFBP-6, in contrast to DPCs from balding scalps.74
Table 3
Stem cell factors and small molecules that promote hair growth and their mechanisms of action
| Factor | Mechanism of action |
|---|---|
| HGF and HGF activator61 | Factor secreted by DPC that promotes proliferation of epithelial follicular cells |
| EGF60 | Promotes growth and migration of follicle ORS cells by activation of Wnt/ß-catenin signaling |
| bFGF62 | Promotes the development of hair follicle |
| IL-693 | Involved in WIHN through STAT3 activation |
| VEGF72 | Promotes perifollicular angiogenesis |
| TGF-ß63 | Stimulates the signaling pathways that regulate hair cycle |
| IGF-169 | Promotes proliferation, survival, and migration of hair follicle cells |
| IGFBP-1 to -670 | Regulates IGF-1 effects and its interaction with extracellular matrix proteins at the hair follicle level |
| BMP23 | Maintains DPC phenotype which is crucial for stimulation of hair follicle stem cell |
| BMPR1a23 | Maintains the proper identity of DPCs that is essential for specific DPC function |
| M-CSF71 | Involved in wound-induced hair regrowth |
| M-CSFR71 | Involved in wound-induced hair regrowth |
| PDGF and PDGFR-ß/-a64 | Upregulates the genes involved in hair follicle differentiation. Induction and regulation of anagen phase. PDGF and its receptors are essential for follicular development |
| Wnt3a97 | Involved in hair follicle development through ß-catenin signaling |
| PGE279,80 | Stimulates anagen phase in hair follicles |
| PGF2a and analogs79,80 | Promotes transition from telogen to anagen phase of the hair cycle |
| BIO98 | GSK-3 inhibitor |
| PGE2 or inhibition of PGD2 or PGD2 receptor D2/GPR4477 | Promotes follicle regeneration |
| Iron and l-lysine95 | Under investigation |
Abbreviations: bFGF, basic fibroblast growth factor; BIO, (2’Z,3’E)-6-bromoindirubin-3′-oxime; BMP, bone morphogenetic protein; DPCs, dermal papilla cells; EGF, epidermal growth factor; GSK-3, glycogen synthase kinase-3; HGF, hepatocyte growth factor; IGF-1, insulin-like growth factor 1; IGFBP-1, insulin-like growth factor-binding protein 1; IL-6, interleukin-6; M-CSF, microphage colony-stimulating factor; M-CSFR, microphage colony-stimulating factor receptor; ORS, outer root sheath; PDGF, platelet-derived growth factor; PDGFR-a, platelet-derived growth factor receptor alpha; PDGFR-ß, platelet-derived growth factor receptor beta; PGD2, prostaglandin D2; PGE2, prostaglandin E2; TGF-ß1, transforming growth factor ß1; VEGF, vascular endothelial growth factor; WIHN, wound-induced hair neogenesis; Wnt3a, wingless-type MMTV integration site family, member 3A.
Small molecules
Small molecules with low molecular weight (<900 Da) and the size of 10-9 m are organic compounds that are able to regulate some biologic processes.75 Some small molecules have been tested for their role in hair growth.76 Synthetic, non-peptidyl small molecules that act as agonists of the hedgehog pathway have the ability to promote follicular cycling in adult mouse skin.76 PGE2 and prostaglandin D2 (PGD2) have also been associated with the hair cycle (Table 3).77 PGD2 is elevated in the scalp of balding men and inhibits hair lengthening via GPR44 receptor.78 Also, it is known that PGE2 and PGF2a promote hair growth, while PGD2 inhibits this process.77,79 Prostaglandin analogs of PGF2a have been used originally to decrease ocular pressure in glaucoma with parallel effects in the growth of eyelashes, which suggests a specific effect in HF activation.80 PGD2 receptors are located in the upper and lower ORS region and in the DP, suggesting that these prostaglandins play an important role in hair cycle.81 Molecules such as quercetin are able to inhibit PGD2 and, in this way, promote hair growth.82–84 Antagonists of PGD2 receptor (formally named chemoattractant receptor-homologous expressed in Th2 cells) such as setipiprant have been used to treat allergic diseases such as asthma, but they also have beneficial effects in AGA.85–87 Another small molecule l-ascorbic acid 2-phosphate promotes proliferation of ORS keratinocytes through the secretion of IGF-1 from DPCs via phosphatidylinositol 3-kinase.88 Recently, it has been described that small-molecule inhibitors of Janus kinase–signal transducer and activator of transcription (JAK-STAT) pathway promote hair regrowth in humans.89 Janus kinase inhibitors are currently approved by the FDA for the treatment of some specific diseases such as psoriasis and other autoimmune-mediated diseases.90–94 Also, another group of small molecules such as iron and the amino acid l-Lysine are essential for hair growth (Table 3).95
Cellular therapy
The multipotent SCs in the bulge region of the HF receive signals from DPCs in order to proliferate and survive.27,28,65,84,96 It has been shown that Wnt/ß-catenin signaling is essential for the growth and maintenance of DPCs.19,97 These cells can be isolated and cultured in vitro with media supplemented with 10% fetal bovine serum and FGF-2.37,98 However, they lose versican expression that correlates with decrease in follicle-inducing activity in culture.98 Versican is the most abundant component of HF extracellular matrix.99 Inhibition of glycogen synthase kinase-3 by (2’Z,3’E)-6-bromoindirubin-3′-oxime (BIO) promotes hair growth in mouse vibrissa follicles in culture by activation of Wnt signaling.98 Therefore, the increase of Wnt signaling in DPCs apparently is one of the main factors that promote hair growth.19 DPCs have been also generated from human embryonic SCs that induced HF formation after murine transplantation.27
Platelet-rich plasma
Platelets are anucleate cells generated by fragmentation of megakaryocytes in the bone marrow.100 These cells are actively involved in the hemostatic process after releasing biologically active molecules (cytokines).100–102 Because of the platelets’ higher capacity to produce and release these factors, autologous platelet-rich plasma (PRP) has been used to treat chronic wounds.103 Therefore, PRP can be used as autologous therapy for regenerative purposes, for example, chondrogenic differentiation, wound healing, fat grafting, AGA, alopecia areata, facial scars, and dermal volume augmentation.101,104–108 PRP contains human platelets in a small volume that is five to seven times higher than in normal blood and it has been proven to be beneficial to treat AGA.10,105,109–111 The factors released by these platelets after their activation, such as PDGFs (PDGFaa, PDGFbb, PDGFab), TGF-ß1, TGF-ß2, EGF, VEGF, and FGF, promote proliferation of DPCs and, therefore, may be beneficial for AGA treatment.109,112–114 Clinical experiments indicate that patients with AGA treated with autologous PRP show improved hair count and thickness.109
In search of novel therapies
In this paper, we reviewed and discussed the use of therapeutic agents for hair regeneration and the knowledge to promote the development of new therapies for AGA based on the advances in regenerative medicine. The HF is a complex structure that grows when adequate signaling is provided to the HFSCs. These cells are located in the follicle bulge and receive signals from MSCs located in the dermis that are called DPCs. The secretory phenotype of DPCs is determined by local and circulatory signals or hormones. Recent discoveries have demonstrated that SCs in culture are able to activate DPCs and HFSCs and, in this way, promote hair growth. The study of these cellular signals can provide the necessary knowledge for developing more effective therapeutic agents for the treatment of AGA with minimal side effects. Therefore, advancements in the field of regenerative medicine may generate novel therapeutic alternatives. However, further research and clinical studies are needed to evaluate their efficacy.
Disclosure
The authors report no conflicts of interest in this work.
References
|
Blumeyer A, Tosti A, Messenger A, et al; European Dermatology Forum (EDF). Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men. J Dtsch Dermatol Ges. 2011;9(Suppl 6):S1–S57. |
||
|
Ramos PM, Miot HA. Female pattern hair loss : a clinical and pathophysiological review. An Bras Dermatol. 2015;90(4):529–543. |
||
|
Otberg N, Finner AM, Shapiro J. Androgenetic alopecia. Endocrinolo Metab Clin North Am. 2007;36(2):379–398. |
||
|
Plikus MV, Chuong CM. Complex hair cycle domain patterns and regenerative hair waves in living rodents. J Invest Dermatol. 2008;128(5):1071–1080. |
||
|
McElwee KJ, Shapiro JS. Promising therapies for treating and/or preventing androgenic alopecia. Skin Therapy Lett. 2012;17(6):1–4. |
||
|
Perez-Mora N, Velasco C, Bermüdez F. Oral finasteride presents with sexual-unrelated withdrawal in long-term treated androgenic alopecia in men. Skinmed. 2015;13(3):179–183. |
||
|
Gupta AK, Charrette A. Topical minoxidil: systematic review and meta-analysis of its efficacy in androgenetic alopecia. Skinmed. 2015;13(3):185–189. |
||
|
Shapiro J, Kaufman KD. Use of finasteride in the treatment of men with androgenetic alopecia (male pattern hair loss). J Investig Dermatol Symp Proc. 2003;8(1):20–23. |
||
|
Rossi A, Anzalone A, Fortuna MC, et al. Multi-therapies in androgenetic alopecia: review and clinical experiences. Dermatol Ther. 2016;29(6):424–432. |
||
|
Varothai S, Bergfeld WF. Androgenetic alopecia: an evidence-based treatment update. Am J Clin Dermatol. 2014;15(3):217–230. |
||
|
Rossi A, Cantisani C, Melis L, Iorio A, Scali E, Calvieri S. Minoxidil use in dermatology, side effects and recent patents. Recent Pat Inflamm Allergy Drug Discov. 2012;6(2):130–136. |
||
|
Motofei IG, Rowland DL, Georgescu SR, Mircea T, Baleanu BC, Paunica S. Are hand preference and sexual orientation possible predicting factors for finasteride adverse effects in male androgenic alopecia? Exp Dermatol. 2016;25(7):557–558. |
||
|
Reijo Pera RA, Gleeson JG. Stems cells and regeneration: special review issue. Hum Mol Gen. 2008;17(R1):R1–R2. |
||
|
Jain R, De-Eknamkul W. Potential targets in the discovery of new hair growth promoters for androgenic alopecia. Expert Opin Ther Targets. 2014;18(7):787–806. |
||
|
Park BS, Kim WS, Choi JS, et al. Hair growth stimulated by conditioned medium of adipose-derived stem cells is enhanced by hypoxia : evidence of increased growth factor secretion. Biomed Res. 2010;31(1):27–34. |
||
|
Fukuoka H, Suga H. Hair regeneration treatment using adipose-derived stem cell conditioned medium :follow-up with trichograms. Eplasty. 2015;15:65–72. |
||
|
Du Y, Roh DS, Funderburgh ML, et al. Adipose-derived stem cells differentiate to keratocytes in vitro. Mol Vis. 2010;16:2680–2689. |
||
|
Zhang P, Kling RE, Ravuri SK, et al. A review of adipocyte lineage cells and dermal papilla cells in hair follicle regeneration. J Tissue Eng. 2014;5:2041731414556850. |
||
|
Tsai SY, Sennett R, Rezza A, et al. Wnt/ß-catenin signaling in dermal condensates is required for hair follicle formation. Dev Biol. 2014;385(2):179–188. |
||
|
Choi YS, Zhang Y, Xu M, et al. Distinct functions for Wnt/ß-catenin in hair follicle stem cell proliferation and survival and interfollicular epidermal homeostasis. Cell Stem Cell. 2013;13(6):720–733. |
||
|
Rao TP, Kuhl M. An updated overview on Wnt signaling pathways a prelude for more. Circ Res. 2010;106(12):1798–1806. |
||
|
Yano K, Brown LF, Detmar M. Control of hair growth and follicle size by VEGF-mediated angiogenesis. J Clin Invest. 2001;107(4):409–417. |
||
|
Rendl M, Polak L, Fuchs E. BMP signaling in dermal papilla cells is required for their hair follicle-inductive properties. Genes Dev. 2008;22(4):543–557. |
||
|
Talavera-Adame D, Gupta A, Kurtovic S, Chaiboonma KL, Arumugaswami V, Dafoe DC. Bone morphogenetic protein-2/-4 upregulation promoted by endothelial cells in coculture enhances mouse embryoid body differentiation. Stem Cells Dev. 2013;22(24):3252–3260. |
||
|
Talavera-Adame D, Wu G, He Y, et al. Endothelial Cells in Co-culture Enhance Embryonic Stem Cell Differentiation to Pancreatic Progenitors and Insulin-Producing Cells through BMP Signaling. Stem Cell Rev. 2011;7(3):532–543. |
||
|
Talavera-Adame D, Ng TT, Gupta A, Kurtovic S, Wu GD, Dafoe DC. Characterization of microvascular endothelial cells isolated from the dermis of adult mouse tails. Microvascular Res. 2011;82(2):97–104. |
||
|
Gnedeva K, Vorotelyak E, Cimadamore F, et al. Derivation of hair-inducing cell from human pluripotent stem cells. PLoS One. 2015;10(1):1–14. |
||
|
Lavker RM, Sun T, Oshima H, et al. Hair follicle stem cells. J Investig Dermatol Symp Proc. 2003;8(1):28–38. |
||
|
Bernard B. Advances in understanding hair growth. F1000Res. 2016;5:1–8. |
||
|
Lay K, Kume T, Fuchs E. FOXC1 maintains the hair follicle stem cell niche and governs stem cell quiescence to preserve long-term tissue-regenerating potential. Proc Natl Acad Sci U S A. 2016;113(1): E1506–E1515. |
||
|
Leirós GJ, Attorresi AI, Balañá ME. Hair follicle stem cell differentiation is inhibited through cross-talk between Wnt/ß-catenin and androgen signalling in dermal papilla cells from patients with androgenetic alopecia. Br J Dermatol. 2012;166(5):1035–1042. |
||
|
Chacon-Martinez CA, Klose M, Niemann C, Glauche I, Wickström SA. Hair follicle stem cells= cultures reveal self-organizing plasticity of stem cells and their progeny. EMBO J. 2017;36(2):151–164. |
||
|
Soler AP, Gilliard G, Megosh LC, O’Brien TG. Modulation of murine hair follicle function by alterations in ornithine decarboxylase activity. J Invest Dermatol. 1996;106(5):1108–1113. |
||
|
Hsu YC, Pasolli HA, Fuchs E. Dynamics between stem cells, nich and progeny in the hair follicle. Cell. 2011;144(1):92–105. |
||
|
Kang JI, Kim SC, Kim MK, et al. Effects of dihydrotestosterone on rat dermal papilla cells in vitro. Eur J Pharmacol. 2015;757:74–83. |
||
|
Yamana K, Labrie F, Luu-The V. Human type 3 5a-reductase is expressed in peripheral tissues at higher levels than types 1 and 2 and its activity is potently inhibited by finasteride and dutasteride. Horm Mol Biol Clin Investig. 2010;2(3):293–299. |
||
|
Osada A, Iwabuchi T, Kishimoto J, Hamazaki TS, Okochi H. Long-term culture of mouse vibrissal dermal papilla cells and de novo hair follicle induction. Tissue Eng. 2007;13(5):975–982. |
||
|
Choi GS, Kim JH, Oh SY, et al. Safety and tolerability of the dual 5-alpha reductase inhibitor dutasteride in the treatment of androgenetic alopecia. Ann Dermatol. 2016;28(4):444–450. |
||
|
Carson C 3rd, Rittmaster R. The role of dihydrotestosterone in benign prostatic hyperplasia. Urology. 2003;61(4 Suppl 1):2–7. |
||
|
Kamimura A, Takahashi T. Procyanidin B-2, extracted from apples, promotes hair growth: a laboratory study. Br J Dermatol. 2002;146(1):41–51. |
||
|
Kamimura A, Takahashi T. Procyanidin B-3, isolated from barley and identified as a hair-growth stimulant, has the potential to counteract inhibitory regulation by TGF-beta1. Exp Dermatol. 2002;11(6):532–541. |
||
|
Ulbricht C, Basch E, Bent S, et al. Evidence-based systematic review of saw palmetto by the Natural Standard Research Collaboration. J Soc Integr Oncol. 2006;4(4):170–186. |
||
|
Rondanelli M, Perna S, Peroni G, Guido D. A bibliometric study of scientific literature in Scopus on botanicals for treatment of androgenetic alopecia. J Cosmet Dermatol. 2015;15(2):120–130. |
||
|
Blume-Peytavi U, Kunte C, Krisp A, Garcia Bartels N, Ellwanger U, Hoffmann R. [Comparison of the efficacy and safety of topical minoxidil and topical alfatradiol in the treatment of androgenetic alopecia in women.] J Dtsch Dermatol Ges. 2007;5(5):391–395. German. |
||
|
Farivar S, Malekshahabi T, Shiari R. Biological effects of low level laser therapy. J Lasers Med Sci. 2014;5(2):58–62. |
||
|
Maiman TH. Biomedical lasers evolve toward clinical applications. Hosp Manage. 1966;101(4):39–41. |
||
|
Cung H, Dai T, Sharma SK, et al. The nuts and bolts of low-level laser (light) therapy. Ann Biomed Eng. 2013;40(2):516–533. |
||
|
Bjordal JM, Couppé C, Chow RT, Tunér J, Ljunggren EA. A systematic review of low level laser therapy with location-specific doses for pain from chronic joint disorders. The Aust J Physiother. 2003;49(2):107–116. |
||
|
Brosseau L, Welch V, Wells G, et al. Low level laser therapy (classes I, II and III) in the treatment of rheumatoid arthritis. Cochrane Database Syst Rev. 2005;19(2):CD002049. |
||
|
Cauwels RGEC, Martens LC. Low level laser therapy in oral mucositis: a pilot study. Eur Arch Paediatr Dent. 2011;12(2):118–123. |
||
|
Schindl A, Schindl M, Pernerstorfer-Schön H, Schindl L. Low-intensity laser therapy: a review. J Investig Med. 2000;48(5):312–326. |
||
|
Liu H, Colavitti R, Rovira II, Finkel T. Redox-dependent transcriptional regulation. Cir Res. 2005;97(10):967–974. |
||
|
Gupta AK, Lyons DCA, Abramovits W. Low-level laser/light therapy for androgenetic alopecia. Skinmed. 2014;12(3):145–147. |
||
|
Jimenez JJ, Wikramanayake TC, Bergfeld W, et al. Efficacy and safety of a low-level laser device in the treatment of male and female pattern hair loss: a multicenter, randomized, sham device-controlled, double-blind study. Am J Clin Dermat. 2014;15(2):115–127. |
||
|
Chen CH, Hung HS, Hsu SH. Low-energy laser irradiation increases endothelial cell proliferation, migration, and eNOS gene expression possibly via PI3K signal pathway. Lasers Surg Med. 2008;40(1):46–54. |
||
|
Tuby H, Maltz L, Oron U. Modulations of VEGF and iNOS in the rat heart by low level laser therapy are associated with cardioprotection and enhanced angiogenesis. Lasers Surg Med. 2006;38(7):682–688. |
||
|
Avci P, Gupta GK, Clark J, Wikonkal N, Hamblin MR. Low-level laser (light) therapy (LLLT) for treatment of hair loss. Laser Surg Med. 2015;46(2):144–151. |
||
|
Rodrigues C, de Assis AM, Moura DJ, et al. New therapy of skin repair combining adipose-derived mesenchymal stem cells with sodium carboxymethylcellulose scaffold in a pre-clinical rat model. PloS One. 2014;9(5):e96241. |
||
|
Gimble JM, Katz AJ, Bunnell BA. Adipose-derived stem cells for regenerative medicine. Cir Res. 2007;100(9):1249–1260. |
||
|
Zhang H, Nan W, Wang S, et al. Epidermal growth factor promotes proliferation and migration of follicular outer root sheath cells via Wnt/ß-catenin signaling. Cell Physiol Biochem. 2016;39(1):360–370. |
||
|
Lee YR, Yamazaki M, Mitsui S, Tsuboi R, Ogawa H. Hepatocyte growth factor (HGF) activator expressed in hair follicles is involved in in vitro HGF-dependent hair follicle elongation. J Dermatol Sci. 2001;25(2):156–163. |
||
|
du Cros DL. Fibroblast growth factor influences the development and cycling of murine hair follicles. Dev Biol. 1993;156(2):444–453. |
||
|
Niimori D, Kawano R, Felemban A, et al. Tsukushi controls the hair cycle by regulating TGF-ß1 signaling. Dev Biol. 2012;372(1):81–87. |
||
|
Tomita Y, Akiyama M, Shimizu H. PDGF isoforms induce and maintain anagen phase of murine hair follicles. J Dermatol Sci. 2006;43(2):105–115. |
||
|
Ohyama M, Terunuma A, Tock CL, et al. Characterization and isolation of stem cell – enriched human hair follicle bulge cells. J Clin Invest. 2006;116(1):249–260. |
||
|
Grayson WL, Zhao F, Bunnell B, Ma T. Hypoxia enhances proliferation and tissue formation of human mesenchymal stem cells. Biochem Biophys Res Commun. 2007;358(3):948–953. |
||
|
Potier E, Ferreira E, Andriamanalijaona R, et al. Hypoxia affects mesenchymal stromal cell osteogenic differentiation and angiogenic factor expression. Bone. 2007;40(4):1078–1087. |
||
|
Ren H, Cao Y, Zhao Q, et al. Proliferation and differentiation of bone marrow stromal cells under hypoxic conditions. Biochem Biophys Res Commun. 2006;347(1):12–21. |
||
|
Su HY, Hickford JG, Bickerstaffe R, Palmer BR. Insulin-like growth factor 1 and hair growth. Dermatol Online J. 1999;5(2):1. |
||
|
Batch JA, Mercuri FA, Werther GA. Identification and localization of insulin-like growth factor-binding protein (IGFBP) messenger RNAs in human hair follicle dermal papilla. J Invest Dermatol. 1996;106(3):471–475. |
||
|
Osaka N, Takahashi T, Murakami S, et al. ASK1-dependent recruitment and activation of macrophages induce hair growth in skin wounds. J Cell Biol. 2007;176(7):903–909. |
||
|
Yano K, Brown LF, Detmar M. Control of hair growth and follicle size by VEGF-mediated angiogenesis. J Clin Invest. 2001;107(4):409–417. |
||
|
Takakura N, Yoshida H, Kunisada T, Nishikawa S, Nishikawa SI. Involvement of platelet-derived growth factor receptor-a in hair canal formation. J Invest Dermatol. 1996;107(5):770–777. |
||
|
Panchaprateep R, Asawanonda P. Insulin-like growth factor-1: roles in androgenetic alopecia. Exp Dermatol. 2014;23(3):216–218. |
||
|
Castoreno AB, Eggert US. Small molecule probes of cellular pathways and networks. ACS Chem Biol. 2011;6(1):86–94. |
||
|
Paladini RD, Saleh J, Qian C, Xu GX, Rubin LL. Modulation of hair growth with small molecule agonists of the hedgehog signaling pathway. J Iinvest Dermatol. 2005;125(4):638–646. |
||
|
Nieves A, Garza LA. Does prostaglandin D2 hold the cure to male pattern baldness? Exp Dematol. 2014;(29):224–227. |
||
|
Nelson AM, Loy DE, Lawson JA, Katseff AS, Fitzgerald GA, Garza LA. Prostaglandin D2 inhibits wound-induced hair follicle neogenesis through the receptor Gpr44. J Invest Dermatol. 2013;133(4):881–889. |
||
|
Sasaki S, Hozumi Y, Kondo S. Influence of prostaglandin F2alpha and its analogues on hair regrowth and follicular melanogenesis in a murine model. Exp Dermatol. 2005;14(5):323–328. |
||
|
Choi YM, Diehl J, Levins PC. Promising alternative clinical uses of prostaglandin F2a analogs: beyond the eyelashes. J Am Acad Dermatol. 2015;72(4):712–716. |
||
|
Colombe L, Michelet JF, Bernard BA. Prostanoid receptors in anagen human hair follicles. Exp Dermatol. 2008;17(1):63–72. |
||
|
Zhang Q, Major MB, Takanashi S, et al. Small-molecule synergist of the Wnt/beta-catenin signaling pathway. Proc Natl Acad Sci U S A. 2007;104(18):7444–7448. |
||
|
Fong P, Tong HH, Ng KH, Lao CK, Chong CI, Chao CM. In silicoprediction of prostaglandin D2 synthase inhibitors from herbal constituents for the treatment of hair loss. J Ethnopharmacol. 2015;175:470–480. |
||
|
Weng Z, Zhang B, Asadi S, et al. Quercetin is more effective than cromolyn in blocking human mast cell cytokine release and inhibits contact dermatitis and photosensitivity in humans. PloS One. 2012;7(3):e33805. |
||
|
Norman P. Update on the status of DP2 receptor antagonists; from proof of concept through clinical failures to promising new drugs. Expert Opin Investig Drugs. 2014;23(1):55–66. |
||
|
Pettipher R. The roles of the prostaglandin D(2) receptors DP(1) and CRTH2 in promoting allergic responses. Br J Pharmacol. 2008;153(Suppl 1):S191–S199. |
||
|
Garza LA, Liu Y, Yang Z, et al. Prostaglandin D2 inhibits hair growth and is elevated in bald scalp of men with androgenetic alopecia. Sci Transl Med. 2012;4(126):126ra34. |
||
|
Kwack MH, Shin SH, Kim SR, et al. I-Ascorbic acid 2-phosphate promotes elongation of hair shafts via the secretion of insulin-like growth factor-1 from dermal papilla cells through phosphatidylinositol 3-kinase. Br J Dermatol. 2009;160(6):1157–1162. |
||
|
Harel S, Higgins CA, Cerise JE, et al. Pharmacologic inhibition of JAK-STAT signaling promotes hair growth. Sci Adv. 2015;1(9):e1500973. |
||
|
Quintás-cardama A, Vaddi K, Liu P, et al. INCB018424 : therapeutic implications for the treatment of myeloproliferative neoplasms Preclinical characterization of the selective JAK1 / 2 inhibitor INCB018424 : therapeutic implications for the treatment of myeloproliferative neoplasms. Blood. 2014;115(15):3109–3117. |
||
|
Geyer HL, Mesa RA. Therapy for myeloproliferative neoplasms: when, which agent, and how? Hematology Am Soc Hematol Educ Program. 2014;2014(1):277–286. |
||
|
Ghoreschi K, Jesson MI, Li X, et al. Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J Immunol. 2012;186(7):4234–4243. |
||
|
Kontzias A, Laurence A, Gadina M, O’Shea JJ. Kinase inhibitors in the treatment of immune-mediated disease. F1000 Med Rep. 2012;4:5. |
||
|
Bao L, Zhang H, Chan LS. The involvement of the JAK-STAT signaling pathway in chronic inflammatory skin disease atopic dermatitis. JAKSTAT. 2013;2(3):1–8. |
||
|
Rushton DH. Nutritional factors and hair loss. Clin Exp Dermatol. 2002;27(5):396–404. |
||
|
Oshima H, Rochat A, Kedzia C, Kobayashi K, Barrandon Y. Morphogenesis and renewal of hair follicles from adult multipotent stem cells. Cell. 2001;104(2):233–245. |
||
|
Huelsken J, Vogel R, Erdmann B, Cotsarelis G, Birchmeier W. beta-Catenin controls hair follicle morphogenesis and stem cell differentiation in the skin. Cell. 2001;105(4):533–545. |
||
|
Yamauchi K, Kurosaka A. Inhibition of glycogen synthase kinase-3 enhances the expression of alkaline phosphatase and insulin-like growth factor-1 in human primary dermal papilla cell culture and maintains mouse hair bulbs in organ culture. Arch Dermatol Res. 2009;301(5):357–365. |
||
|
Sotoodehnejadnematalahi F, Burke B. Structure, function and regulation of versican: the most abundant type of proteoglycan in the extracellular matrix. Acta Med Iran. 2013;51(11):740–750. |
||
|
Xu XR, Zhang D, Oswald BE, et al. Platelets are versatile cells: new discoveries in hemostasis, thrombosis, immune responses, tumor metastasis and beyond. Crit Rev Clin Lab Sci. 2016;53(6):409–430. |
||
|
Lacci KM, Dardik A. Platelet-rich plasma: support for its use in wound healing. Yale J Biol Med. 2010;83(1):1–9. |
||
|
Mussano F, Genova T, Munaron L, Petrillo S, Erovigni F, Carossa S. Cytokine, chemokine, and growth factor profile of platelet-rich plasma. Platelets. 2016;27(5):467–471. |
||
|
Martinez-Zapata MJ, Martí-Carvajal AJ, Solà I, et al. Autologous platelet-rich plasma for treating chronic wounds. Cochrane Database Syst Rev. 2016;(5):CD006899. |
||
|
Modarressi A. Platlet Rich Plasma (PRP) improves fat grafting outcomes. World J Plast Surg. 2013;2(1):6–13. |
||
|
Gentile P, Garcovich S, Bielli A, Scioli MG, Orlandi A, Cervelli V. The Effect of platelet-rich plasma in hair regrowth: a randomized placebo-controlled trial. Stem Cells Transl Med. 2015;4(11):1317–1323. |
||
|
Lynch MD, Bashir S. Applications of platelet-rich plasma in dermatology: a critical appraisal of the literature. J Dermatolog Treat. 2016;27(3):285–289. |
||
|
Trink A, Sorbellini E, Bezzola P, et al. A randomized, double-blind, placebo- and active-controlled, half-head study to evaluate the effects of platelet-rich plasma on alopecia areata. Br J Dermatol. 2013;169(3):690–694. |
||
|
Oh Y, Kim BJ, Kim MN. Depressed facial scars successfully treated with autologous platelet-rich plasma and light-emitting diode phototherapy at 830 nm. Ann Dermatol. 2014;26(3):417–418. |
||
|
Singhal P, Agarwal S, Dhot PS, Sayal SK. Efficacy of platelet-rich plasma in treatment of androgenic alopecia. Asian J Transfus Sci. 2015;9(2):159–162. |
||
|
Valente Duarte de Sousa IC, Tosti A. New investigational drugs for androgenetic alopecia. Expert Opin Investig Drugs. 2013;22(5):573–589. |
||
|
Alves R, Grimalt R. Randomized placebo-controlled, double-blind, half-head study to assess the efficacy of platelet-rich plasma on the treatment of androgenetic alopecia. Dermatol Surg. 2016;42(4):491–497. |
||
|
Cho JW, Kim SA, Lee KS. Platelet-rich plasma induces increased expression of G1 cell cycle regulators, type I collagen, and matrix metalloproteinase-1 in human skin fibroblasts. Int J Mol Med. 2012;29(1):32–36. |
||
|
Mehta V. Platelet-rich plasma: a review of the science and possible clinical applications. Orthopedics. 2010;33(2):111. |
||
|
Leo MS, Kumar AS, Kirit R, Konathan R, Sivamani RK. Systematic review of the use of platelet-rich plasma in aesthetic dermatology. J Cosmet Dermatol. 2015;14(4):315–323. |
- Published in Blog
ISSCA introduces new stem cell training courses web page for regenerative medicine practitioners
ISSCA has launched a new stem cell training web page designed to offer free information and resources to help physicians choose a training program best suited to their unique needs.
MIAMI, June 26, 2018—The International Society for Stem Cell Application (ISSCA) has launched a new stem cell training course web page, coordinated by Global Stem Cells Group affiliate Stem Cell Training, designed to help physicians access free information and resources on the newest instruction and training options in regenerative medicine training.
The new web page is designed to help physicians interested in adding stem cell procedures to grow their medical practice or enhance career advancement opportunities find stem cell training program options to enable them to find a training program best suited to their individual needs. ISSCA’s variety of stem cell training opportunities include:
• Online stem cell training course, ISSCA’s cutting-edge online course that teaches physicians everything they need to know to add adult stem cell-based procedures to their existing practice, or confidently transition to a regenerative medicine center. Offering the convenience of training from a home or office computer, this course prepares physicians in all the theoretical and practical knowledge needed to effectively and expertly administer stem cell therapies to patients, including harvesting and isolating stem cells.
ISSCA’s online training positions physicians to open their own stem cell center practice and join ISSCA’s expansive network. Successful completion of the online training course allows physicians to immediately begin offering cutting-edge regenerative medicine procedures to patients, establish themselves as experts in their fields, and enjoy the benefits of the growing regenerative medicine industry.
• Hands-on stem cell certification training courses, ISCCA’s intensive, two-day hands-on training course scheduled at various international locations provides attending physicians with expert instruction on autologous stem cell therapies in the field of regenerative medicine. Participants learn techniques and protocols for harvesting and isolating stem and regenerative cells from adipose tissue, bone marrow, and /or peripheral blood from live patients and administering the cells back to the patient
Course curriculum consists of comprehensive theoretical lectures and home study education, and two days of didactic and clinical experience. One day of post-educational on-site clinical assistance is also available upon request.
• Onsite training, ISSCA’s personalized, hands-on, onsite stem cell training brings stem cell specialists to your practice or clinic, anywhere in the world, to provide one-on-one training tailored to your practice’s specific requirements—saving time and money. The onsite training program offers participants a unique opportunity to grow their practice and achieve their specific practice goals by offering practice-specific regenerative medicine treatments to patients in their medical office or clinical setting.
The onsite training course provides participating practices with personalized theoretical information and hands-on training along with ongoing support for their clinical practice. Applications and protocols are provided by a Stem Cells Training faculty member with extensive experience in laboratory and clinical practice.
ISSCA’s onsite training specifications include:
1. Equipment and supply delivery. The Stem Cell Training team
delivers and sets up all equipment and supplies necessary for the training session to take place and will leave the physician’s team
fully qualified to start its own stem cell treatment practice.
2. Expert trainers. ISSCA’s onsite stem cell training course takes a highly visual and interactive approach. Expert trainers teach and supervise the hands-on process using live patients and different protocols for the extraction, isolation, and application of PRP, adipose- and bone marrow-derived stem cells.
3. Multimedia access. ISSCA provides physicians participating in its onsite training program access to its library of high-resolution, step-by-step procedure videos and ongoing online and telephone support for clinical equipment, inquiries or concerns for the practice’s future use and reference.
• Fellowship in cell therapy and tissue engineering. Recognizing the need for knowledge of stem cell protocols among physicians and healthcare professionals, ISSCA and Stem Cell Training created the Fellowship of Stem Cell Therapy and Tissue Engineering program. The fellowship focuses on stem cell therapies involving the potential replacement of cells or organs that are diseased, injured, infirmed, ailing or aged
In this modular training program, a group of experienced academic scholars involved in stem cell transplantation present a series of topics covering the general principles and practices of stem cell
biology and evidence-based treatments that physicians can apply to optimize the health of their patients. Fellowship course details and objectives include:
• A detailed program offering hands-on experience in stem cell characterization and laboratory applications
• An opportunity to learn cell culture processes including plating, trypsinization, harvesting, and cryopreservation
• Gaining the ability to understand and apply quality control tests including cell count, viability, flow cytometry, endotoxin, mycoplasma, and sterility
• Learning to perform CGMP functions including clean room maintenance, gowning, and environmental monitoring
• Establishing insight on relevant applications of stem cell processing and regulations that apply to a certified facility
• Receiving the tools necessary to implement regulatory and clinical guidelines when setting up a GMP facility
• Providing participants with copies of presentations, procedural protocols, and all forms associated with a GMP facility, as well as case books and full protocols for approximately 30 indications
• Demonstrating the ability to perform clinical procedures including lipoaspirate and bone marrow isolation, and reintroduction of stem cells for various indications
The new ISSCA stem cell training web page also features an informative blog that publishes four new articles in the field of regenerative medicine weekly.
To learn more, visit the ISSCA stem cell training web page, email info@stemcellsgroup.com, or call 305-560-5337.
About ISSCA:
The International Society for Stem Cell Application (ISSCA) is a multidisciplinary community of scientists and physicians, all of whom aspire to treat diseases and lessen human suffering through advances in science, technology and the practice of regenerative medicine. ISSCA serves its members through advancements made in the specialty of regenerative medicine.
The ISSCA’s vision is to take a leadership position in promoting excellence and setting standards in the regenerative medicine fields of publication, research, education, training, and certification.
As a medical specialty, regenerative medicine standards and certifications are essential, which is why ISSCA offers certification training in cities all over the world. The goal is to encourage more physicians to practice regenerative medicine and make it available to benefit patients both nationally and globally. Incorporated under the Republic of Korea as a non-profit entity, ISSCA is focused on promoting excellence and standards in the field of regenerative medicine.
Stem cell training web page launch
- Published in Press Release